Original Article| Volume 23, ISSUE 6, P1409-1415, July 2014

The Effect of Acute Medication with Cilostazol, an Anti-platelet Drug, on the Outcome of Small Vessel Brain Infarction

      Our objective was to investigate the effect of cilostazol in acute therapy for small vessel stroke patients. The neurologic deficits in some patients of small vessel brain infarction will progress even if a patient takes immediate medical treatments including aspirin or other antiplatelet drugs. In Japan, cilostazol, presenting not only the antiplatelet effect but also the arteriole dilation, is used for treatment of ischemic stroke. In this study, acute stroke patients with small vessel occlusion were treated with cilostazol instead of aspirin in the conventional medication after 2010. Therefore, patients between April 2007 and March 2009 were classified into the conventional group (group-con, n = 220), and patients between April 2010 and March 2012 were classified into the cilostazol group (group-cilo, n = 230). Enrolled patients were classified into lacunar infarction (LI) and branch atheromatous disease. Progressing stroke was defined as the increase of National Institutes of Health Stroke Scale score of 2 or more within 48 hours. The clinical outcome was assessed by the modified Rankin Scale (mRS) score at 1 month. As the result, the significant reduction in progressing stroke was dominant in the LI of brainstem (P = .01). The length of hospital stay was significantly shorter in the group-cilo compared with the group-con (18.6 and 21.2 days, P = .03). Moreover, mRS score at 1 month was significantly lower in the group-cilo than the group-con (1.9 and 2.3, P = .03). In conclusion, cilostazol reduced the risk of early neurologic deterioration of patients with small vessel brain infarction. It is eagerly desired to conduct a large randomized control trial.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Stroke and Cerebrovascular Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • The European Stroke Organization (ESO) Executive Committee and the ESO Writing Committee
        Guidelines for management of ischaemic stroke and transient ischaemic attack 2008.
        Cerebrovasc Dis. 2008; 25: 457-507
        • Coull B.M.
        • Williams L.S.
        • Goldstein L.B.
        • et al.
        Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the joint stroke guideline development committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association).
        Stroke. 2002; 33: 1934-1942
        • Klijn C.J.
        • Hankey G.J.
        Management of acute ischaemic stroke: new guidelines from the American Stroke Association and European Stroke Initiative.
        Lancet Neurol. 2003; 2: 698-701
        • Steinke W.
        • Ley S.C.
        Lacunar stroke is the major cause of progressive motor deficits.
        Stroke. 2002; 33: 1510-1516
        • Caplan L.R.
        Intracranial branch atheromatous disease: a neglected, understudied, and underused concept.
        Neurology. 1989; 39: 1246-1250
      1. Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III.
        Stroke. 1990; 21: 637-676
        • Adams Jr., H.P.
        • Bendixen B.H.
        • Kappelle L.J.
        • et al.
        Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.
        Stroke. 1993; 24: 35-41
        • Saia V.
        • Pantoni L.
        Progressive stroke in pontine infarction.
        Acta Neurol Scand. 2009; 120: 213-215
        • Staaf G.
        • Geijer B.
        • Lindgren A.
        • et al.
        Diffusion-weighted MRI findings in patients with capsular warning syndrome.
        Cerebrovasc Dis. 2004; 17: 1-8
        • Kimura Y.
        • Tani T.
        • Kanbe T.
        • et al.
        Effect of cilostazol on platelet aggregation and experimental thrombosis.
        Arzneimittelforschung. 1985; 35: 1144-1149
        • Kambayashi J.
        • Liu Y.
        • Sun B.
        • et al.
        Cilostazol as a unique antithrombotic agent.
        Curr Pharm Des. 2003; 9: 2289-2302
        • Lee J.H.
        • Park S.Y.
        • Shin H.K.
        • et al.
        Protective effects of cilostazol against transient focal cerebral ischemia and chronic cerebral hypoperfusion injury.
        CNS Neurosci Ther. 2008; 14: 143-152
      2. The Joint Committee on Guidelines for the Management of Stroke. Japanese Guidelines for the Management of Stroke 2009. 2009.

        • Nakase T.
        • Yoshioka S.
        • Sasaki M.
        • et al.
        Clinical evaluation of lacunar infarction and branch atheromatous disease.
        J Stroke Cerebrovasc Dis. 2013; 22: 406-412
        • Yamamoto Y.
        • Ohara T.
        • Hamanaka M.
        • et al.
        Characteristics of intracranial branch atheromatous disease and its association with progressive motor deficits.
        J Neurol Sci. 2011; 304: 78-82
        • Castellanos M.
        • Castillo J.
        • Garcia M.M.
        • et al.
        Inflammation-mediated damage in progressing lacunar infarctions: a potential therapeutic target.
        Stroke. 2002; 33: 982-987
        • Yamamoto Y.
        • Ohara T.
        • Hamanaka M.
        • et al.
        Predictive factors for progressive motor deficits in penetrating artery infarctions in two different arterial territories.
        J Neurol Sci. 2010; 288: 170-174
        • Castillo J.
        Deteriorating stroke: diagnostic criteria, predictors, mechanisms and treatment.
        Cerebrovasc Dis. 1999; 9: 1-8
        • Terai S.
        • Hori T.
        • Miake S.
        • et al.
        Mechanism in progressive lacunar infarction: a case report with magnetic resonance imaging.
        Arch Neurol. 2000; 57: 255-258
        • Holt M.R.
        • Critchley D.R.
        • Brindle N.P.
        The focal adhesion phosphoprotein, VASP.
        Int J Biochem Cell Biol. 1998; 30: 307-311
        • Choi J.M.
        • Shin H.K.
        • Kim K.Y.
        • et al.
        Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats.
        J Pharmacol Exp Ther. 2002; 300: 787-793
        • Lee J.H.
        • Oh G.T.
        • Park S.Y.
        • et al.
        Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol.
        J Pharmacol Exp Ther. 2005; 313: 502-509
        • Lee J.H.
        • Kim K.Y.
        • Lee Y.K.
        • et al.
        Cilostazol prevents focal cerebral ischemic injury by enhancing casein kinase 2 phosphorylation and suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation in rats.
        J Pharmacol Exp Ther. 2004; 308: 896-903
        • Lee J.H.
        • Park S.Y.
        • Shin H.K.
        • et al.
        Poly(ADP-ribose) polymerase inhibition by cilostazol is implicated in the neuroprotective effect against focal cerebral ischemic infarct in rat.
        Brain Res. 2007; 1152: 182-190
        • Honda F.
        • Imai H.
        • Ishikawa M.
        • et al.
        Cilostazol attenuates gray and white matter damage in a rodent model of focal cerebral ischemia.
        Stroke. 2006; 37: 223-228
        • Fisher M.
        The ischemic penumbra: a new opportunity for neuroprotection.
        Cerebrovasc Dis. 2006; 21: 64-70
        • Fisher M.
        • Garcia J.H.
        Evolving stroke and the ischemic penumbra.
        Neurology. 1996; 47: 884-888
        • Yamada M.
        • Yoshimura S.
        • Kaku Y.
        • et al.
        Prediction of neurologic deterioration in patients with lacunar infarction in the territory of the lenticulostriate artery using perfusion ct.
        AJNR Am J Neuroradiol. 2004; 25: 402-408
        • Kim S.K.
        • Song P.
        • Hong J.M.
        • et al.
        Prediction of progressive motor deficits in patients with deep subcortical infarction.
        Cerebrovasc Dis. 2008; 25: 297-303
        • Ohara T.
        • Yamamoto Y.
        • Tamura A.
        • et al.
        The infarct location predicts progressive motor deficits in patients with acute lacunar infarction in the lenticulostriate artery territory.
        J Neurol Sci. 2010; 293: 87-91
        • Adachi T.
        • Kobayashi S.
        • Yamaguchi S.
        Frequency and pathogenesis of silent subcortical brain infarction in acute first-ever ischemic stroke.
        Intern Med. 2002; 41: 103-108
        • van Zagten M.
        • Boiten J.
        • Kessels F.
        • et al.
        Significant progression of white matter lesions and small deep (lacunar) infarcts in patients with stroke.
        Arch Neurol. 1996; 53: 650-655